Post-market Study of Multi-Vector Left Ventricular Lead Performance in Chinese Patients With Chronic Heart Failure
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Chronic Heart Failure
- Sponsor
- Abbott Medical Devices
- Enrollment
- 121
- Locations
- 14
- Primary Endpoint
- The Number of Participants With LV Lead-related Serious Adverse Device Effects (SADEs)
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
The purpose of this clinical study is to observe the safety and efficacy of the multi-vector left ventricular (LV) lead in Chinese patients that are indicated for Cardiac Resynchronization Therapy (CRT).
Detailed Description
This is a multi-center, non-randomized observational study. The total duration of the study is expected to be 2.5 years. The clinical study will be conducted in no more than 15 centers in China. Approximately 120 subjects will be enrolled in this study. Subjects will be followed up at 3, 6, 12 months and every 6 months afterwards. All subjects need to be followed for at least 6 months.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Meets the current European Society of Cardiology (ESC) or American College of Cardiology Foundation (ACCF)/American Heart Association (AHA)/Heart Rhythm Society (HRS) Class I or Class IIa indications for CRT implant (including upgrades from single or dual chamber Implantable Cardioverter-Defibrillators (ICDs))
- •Are ≥ 18 years of age at the time of enrolment.
- •Are able to provide written Informed Consent prior to any study related procedure.
Exclusion Criteria
- •Patient who is unable to comply with the follow-up schedule.
- •Patient who has any medical conditions that in the opinion of the investigator will not be appropriate to participate in the study .
- •Patient has a life expectancy of less than 1 year due to any condition.
- •Patients, who has a CRT device implanted
Outcomes
Primary Outcomes
The Number of Participants With LV Lead-related Serious Adverse Device Effects (SADEs)
Time Frame: From implantation to 6 months after implant procedure.
The primary safety endpoint is the number of participants with LV lead-related SADEs compared to the total number of analyzed participants.
Secondary Outcomes
- The Intrinsic QRS Duration of Participants(6 months)
- The Number of Participants With Effective LV Pacing(6 months)
- The Number of Participants in Each NYHA Functional Class(6 months)